As 24/48 (50%) glioma patients were affected by GVs in one of these 10 CPGs, they may be possible candidates for a molecularly targeted therapy, i.e., with PARP inhibitors (16/24, 67%), immune checkpoint inhibitors (ICI) (5/24, 21%), EGFR tyrosine kinase inhibitor (TKI) mono- or combination therapy (2/24, 8%, EGFR is expressed and Tyr1068-phosphorylated in two glioblastomas of patients with EGFR GVs, Supplementary Fig. 9 online resource), or CDK4/6 inhibitors (1/24, 4%) (Fig. 5b). This evidence concerns the gene PARP1 and central nervous system cancer.